Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results
Adaptive Biotechnologies (ADPT) reported strong financial results for Q3 2021, with revenue of $39.5 million, a 50% increase year-over-year. Sequencing revenue saw a remarkable 96% growth, reaching $22.1 million. However, the company faced rising operating expenses of $95.8 million, leading to a net loss of $56.0 million, up from $36.7 million in Q3 2020. They reaffirmed their full-year revenue guidance of $148 million to $155 million, indicating a projected 54% growth compared to 2020. Cash reserves stood at $632.4 million as of September 30, 2021.
- Revenue increased by 50% year-over-year to $39.5 million.
- Sequencing revenue surged by 96% from the previous year.
- Achieved significant clinical advancements, including an enhanced clonoSEQ Assay.
- Net loss increased to $56.0 million, compared to $36.7 million in Q3 2020.
- Operating expenses rose by 51%, totaling $95.8 million.
SEATTLE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2021.
“We are pleased to deliver another quarter of strong growth with continued momentum across research, diagnostic and drug discovery,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “Achievements during the quarter mark important advancements in the evolution of our immune medicine platform as a clinical product development engine.”
Recent Highlights
- Revenue of
$39.5 million for the third quarter 2021, representing a50% increase from the third quarter 2020 - clonoSEQ clinical sequencing volume in the third quarter 2021 grew
47% versus prior year and8% over the second quarter of 2021 - Launched an enhanced version of the clonoSEQ Assay for CLL patients, which provides IGHV mutation status in the same test where we measure the trackable MRD sequence
- Received positive Tech Assessment from MolDX for coverage of T-Detect COVID in certain cases including immunocompromised patients
- Increased interest by research collaborators and vaccine manufacturers to use immunoSEQ T-MAP COVID to assess whether T cells may provide a correlate of protection
- Vaccibody initiated its phase 1/2 study to address emerging SARS-CoV-2 variants of concern and use as a potential universal booster with their two candidates, one of which includes T cell-based components identified by Adaptive Biotechnologies' immune medicine platform
Third Quarter 2021 Financial Results
Revenue was
Operating expenses were
Net loss was
Adjusted EBITDA (non-GAAP) was a loss of
Cash, cash equivalents and marketable securities was
2021 Financial Guidance
Adaptive Biotechnologies reiterates full year 2021 revenue to be in the range of
Webcast and Conference Call Information
Adaptive Biotechnologies will host a conference call to discuss its third quarter 2021 financial results after market close on Wednesday, November 3, 2021 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Use of Non-GAAP Financial Measure
To supplement our unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses. We have provided a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.
Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.
Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:
- all expenditures or future requirements for capital expenditures or contractual commitments;
- changes in our working capital needs;
- income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;
- the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;
- the non-cash component of employee compensation expense; and
- the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.
In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.
ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com
Adaptive Biotechnologies
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue | ||||||||||||||||
| Sequencing revenue | $ | 22,106 | $ | 11,276 | $ | 55,835 | $ | 28,730 | ||||||||
| Development revenue | 17,361 | 15,023 | 60,579 | 39,467 | ||||||||||||
| Total revenue | 39,467 | 26,299 | 116,414 | 68,197 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Cost of revenue | 14,189 | 6,053 | 34,945 | 16,308 | ||||||||||||
| Research and development | 36,072 | 30,314 | 107,644 | 80,241 | ||||||||||||
| Sales and marketing | 24,949 | 14,474 | 68,769 | 42,813 | ||||||||||||
| General and administrative | 20,154 | 12,079 | 51,156 | 36,138 | ||||||||||||
| Amortization of intangible assets | 428 | 428 | 1,270 | 1,275 | ||||||||||||
| Total operating expenses | 95,792 | 63,348 | 263,784 | 176,775 | ||||||||||||
| Loss from operations | (56,325 | ) | (37,049 | ) | (147,370 | ) | (108,578 | ) | ||||||||
| Interest and other income, net | 327 | 1,018 | 1,429 | 5,805 | ||||||||||||
| Income tax (expense) benefit | — | (688 | ) | — | 1,116 | |||||||||||
| Net loss | (55,998 | ) | (36,719 | ) | (145,941 | ) | (101,657 | ) | ||||||||
| Add: Net loss attributable to noncontrolling interest | 95 | — | 95 | — | ||||||||||||
| Net loss attributable to Adaptive Biotechnologies Corporation | $ | (55,903 | ) | $ | (36,719 | ) | $ | (145,846 | ) | $ | (101,657 | ) | ||||
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | $ | (0.40 | ) | $ | (0.27 | ) | $ | (1.04 | ) | $ | (0.79 | ) | ||||
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | 140,833,564 | 134,372,026 | 140,060,379 | 129,289,948 | ||||||||||||
Adaptive Biotechnologies
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, 2021 | December 31, 2020 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 122,401 | $ | 123,436 | ||||
| Short-term marketable securities (amortized cost of | 292,639 | 564,833 | ||||||
| Accounts receivable, net | 17,122 | 10,047 | ||||||
| Inventory | 18,231 | 14,063 | ||||||
| Prepaid expenses and other current assets | 16,634 | 14,535 | ||||||
| Total current assets | 467,027 | 726,914 | ||||||
| Long-term assets | ||||||||
| Property and equipment, net | 87,820 | 39,692 | ||||||
| Operating lease right-of-use assets | 89,446 | 99,350 | ||||||
| Long-term marketable securities (amortized cost of | 217,379 | 118,525 | ||||||
| Restricted cash | 2,138 | 2,138 | ||||||
| Intangible assets, net | 8,955 | 10,225 | ||||||
| Goodwill | 118,972 | 118,972 | ||||||
| Other assets | 870 | 598 | ||||||
| Total assets | $ | 992,607 | $ | 1,116,414 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 8,252 | $ | 3,237 | ||||
| Accrued liabilities | 17,034 | 13,162 | ||||||
| Accrued compensation and benefits | 12,034 | 11,950 | ||||||
| Current portion of operating lease liabilities | 5,108 | 3,529 | ||||||
| Current portion of deferred revenue | 79,954 | 73,319 | ||||||
| Total current liabilities | 122,382 | 105,197 | ||||||
| Long-term liabilities | ||||||||
| Operating lease liabilities, less current portion | 108,044 | 104,333 | ||||||
| Deferred revenue, less current portion | 110,638 | 163,618 | ||||||
| Total liabilities | 341,064 | 373,148 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity | ||||||||
| Preferred stock: | — | — | ||||||
| Common stock: | 14 | 14 | ||||||
| Additional paid-in capital | 1,308,946 | 1,253,971 | ||||||
| Accumulated other comprehensive gain | 7 | 893 | ||||||
| Accumulated deficit | (657,458 | ) | (511,612 | ) | ||||
| Total Adaptive Biotechnologies Corporation shareholders’ equity | 651,509 | 743,266 | ||||||
| Noncontrolling interest | 34 | — | ||||||
| Total shareholders’ equity | 651,543 | 743,266 | ||||||
| Total liabilities and shareholders’ equity | $ | 992,607 | $ | 1,116,414 | ||||
Adjusted EBITDA
The following table sets forth a reconciliation between our Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net loss attributable to Adaptive Biotechnologies Corporation | $ | (55,903 | ) | $ | (36,719 | ) | $ | (145,846 | ) | $ | (101,657 | ) | ||||
| Interest and other income, net | (327 | ) | (1,018 | ) | (1,429 | ) | (5,805 | ) | ||||||||
| Income tax expense (benefit) | — | 688 | — | (1,116 | ) | |||||||||||
| Depreciation and amortization expense | 3,528 | 2,144 | 9,104 | 6,120 | ||||||||||||
| Share-based compensation expense | 11,643 | 6,470 | 31,376 | 17,518 | ||||||||||||
| Adjusted EBITDA | $ | (41,059 | ) | $ | (28,435 | ) | $ | (106,795 | ) | $ | (84,940 | ) | ||||
FAQ
What were Adaptive Biotechnologies' Q3 2021 revenue results?
What was the net loss reported by ADPT for Q3 2021?
What is Adaptive Biotechnologies' revenue guidance for 2021?
How did operating expenses change for ADPT in Q3 2021?
What advancements did ADPT achieve in its clinical products?
